The cancer community remains divided over the efficacy of Avastin, Genentech's colon- and lung-cancer drug, in treating breast cancer, days before the FDA is scheduled to hand down its decision on the drug's expanded use. Genentech says that its approval would provide patients with more treatment options, but some patient advocates say studies have not shown that the drug improves survival or quality of life for breast cancer patients.

Related Summaries